文献速递心外重症与机械循环支持

门诊晚期心衰患者结局:MedaMACS登记研究

Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry.
PubMed 文献 · J Heart Lung Transplant · 2018-10-01

MedaMACS登记研究纳入161例NYHA III–IV级、INTERMACS 4–7级的门诊晚期心衰患者,随访2年时47%达到主要终点(死亡24%、LVAD 11%、移植12%)。与1753例INTERMACS 4–7级LVAD患者比较,总体意向治疗生存无差异,但4–5级患者中LVAD生存优于药物治疗(p=0.0092)。

要点

  • 门诊晚期心衰患者2年预后差,仅53%在药物治疗下存活。
  • INTERMACS 4–5级患者LVAD生存优于药物治疗(p=0.0092)。
  • 应及早考虑移植与LVAD评估以改善此类患者结局。

核心结论

  • 门诊晚期心衰患者不良结局风险高,2年随访时仅53%在药物治疗下存活。
  • 总体队列中医与LVAD意向治疗生存相似,但INTERMACS 4–5级患者LVAD生存更优(p=0.0092)。
  • 鉴于结局较差,及时考虑移植和LVAD至关重要。

研究设计与样本

  • 纳入NYHA III或IV级、INTERMACS 4–7级、接受最佳药物治疗(未用正性肌力药)的门诊晚期心衰患者。
  • 次要意向治疗生存分析将MedaMACS患者与INTERMACS登记中匹配的1753例4–7级LVAD患者比较。

主要发现

  • 入组患者INTERMACS 4级占12%、5级32%、6级49%、7级7%。
  • 2年内75例(47%)达到主要终点:死亡39例(24%)、LVAD植入17例(11%)、移植19例(12%)。
  • 与1753例4–7级LVAD患者比,总体意向治疗生存无差异,但4–5级患者LVAD生存优于药物治疗(p=0.0092)。
  • LVAD患者基线健康相关生活质量低于继续口服药物治疗者,但两组幸存者1年后均改善。

临床怎么用

  • 对门诊晚期心衰(INTERMACS 4–7级)患者应早期评估移植与LVAD指征。
  • INTERMACS 4–5级患者可优先考虑LVAD治疗以改善生存。

局限性

  • 为观察性登记研究,非随机对照,治疗分组可能存在选择偏倚。
  • 样本量161例,随访2年,长期结局未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outlook for ambulatory patients with advanced heart failure (HF) and the appropriate timing for left ventricular assist device (LVAD) or transplant remain uncertain. The aim of this study was to better understand disease trajectory and rates of progression to subsequent LVAD therapy and transplant in ambulatory advanced HF. METHODS: Patients with advanced HF who were New York Heart Association (NYHA) Class III or IV and Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profiles 4 to 7, despite optimal medical therapy (without inotropic therapy), were enrolled across 11 centers and followed for the end-points of survival, transplantation, LVAD placement, and health-related quality of life. A secondary intention-to-treat survival analysis compared outcomes for MedaMACS patients with a matched group of Profile 4 to 7 patients with LVADs from the INTERMACS registry. RESULTS: Between May 2013 and October 2015, 161 patients were enrolled with INTERMACS Profiles 4 (12%), 5 (32%), 6 (49%), and 7 (7%). By 2 years after enrollment, 75 (47%) patients had reached a primary end-point with 39 (24%) deaths, 17 (11%) undergoing LVAD implantation, and 19 (12%) receiving a transplant. Compared with 1,753 patients with Profiles 4 to 7 receiving LVAD therapy, there was no overall difference in intention-to-treat survival between medical and LVAD therapy, but survival with LVAD therapy was superior to medical therapy among Profile 4 and 5 patients (p = 0.0092). Baseline health-related quality of life was lower among patients receiving a LVAD than those enrolled on continuing oral medical therapy, but increased after 1 year for survivors in both cohorts. CONCLUSIONS: Ambulatory patients with advanced HF are at high risk for poor outcomes, with only 53% alive on medical therapy after 2 years of follow-up. Survival was similar for medical and LVAD therapy in the overall cohort, which included the lower severity Profiles 6 and 7, but survival was better with LVAD therapy among patients in Profiles 4 and 5. Given the poor outcomes in this group of advanced HF patients, timely consideration of transplant and LVAD is of critical importance.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Ambardekar AV, Kittleson MM, Palardy M, et al. Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. J Heart Lung Transplant. 2018. PMID: 30948210. doi:10.1016/j.healun.2018.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。